Search Results

Healthcare providers and patients rely on accurate information to make informed decisions. However, public conversation or criticisms can lead to inaccuracies, misinformation, and disinformation, which can cause confusion, erode trust, and result in negative health outcomes.

I am just completing a two-week vacation. My greatest joy is finding a quiet place and devouring a book. Here’s a list of my favorite books that I read this summer.

Just over two years ago, Corporate America found itself at a crossroads. As Americans rose up in the streets to acknowledge the violent truths about our country’s painful manifestations of everyday racism, leaders were forced to look critically at their marketing, their hiring, their supply chains, and—perhaps most critically—themselves.   

Communications, the proper framework, and adequate attention to diverse stakeholders can help yield positive outcomes and better business decisions for companies trying to operate within this dynamic. I was in Washington, DC on Wednesday and sat with Rob Rehg, a 30-year Edelman veteran and my co-pilot on the Penn State crisis a decade ago. Rob and our Issues team have developed a fascinating product, the Societal Issues Navigator, that helps Chief Communications Officers prioritize and manage the multitude of issues confronting business as it seeks to meet the new expectations of all stakeholders including consumers, employees, and investors.

This year’s Edelman Trust Barometer indicates that we are living in a world in which distrust has become the default: 59 percent of people distrust until provided with evidence that something is trustworthy.

The pandemic put a hold on many of the most popular business marketing and sales activities, from trade shows to meet and greets with the CEO as well as business brands sponsoring events and hospitality. 

As we wait to learn the outcome of the election there are a number of things business can do to help keep people calm, informed and feel heard.

The eventual arrival of a vaccine will bring with it a stark reality: there will be between 1.5 and 2 billion doses available for the nearly 8 billion people in the world. How to allocate the scarce and precious gift of prevention is the next issue lying in wait for the pharmaceutical industry and governments after a vaccine is developed.